View Older Stories View More Recent Stories

Apr 1, 2026 06:06AM H.C. Wainwright Downgrades Apellis Pharmaceuticals (APLS) to Neutral

Apr 1, 2026 03:37AM Raymond James Downgrades Apellis Pharmaceuticals (APLS) to Market Perform

Apr 1, 2026 02:52AM Cantor Fitzgerald Downgrades Apellis Pharmaceuticals (APLS) to Neutral

Apr 1, 2026 02:24AM JPMorgan Downgrades Apellis Pharmaceuticals (APLS) to Neutral

Mar 31, 2026 04:08PM Stifel Downgrades Apellis Pharmaceuticals (APLS) to Hold

Mar 31, 2026 01:28PM Guggenheim Reiterates Buy Rating on Biogen (BIIB) following Apellis deal

Mar 31, 2026 01:12PM Jefferies Downgrades Apellis Pharmaceuticals (APLS) to Hold

Mar 31, 2026 12:26PM Apellis Pharmaceuticals (APLS) PT Raised to $41 at Morgan Stanley

Mar 31, 2026 12:23PM Apellis Pharmaceuticals (APLS) PT Raised to $41 at Barclays

Mar 31, 2026 11:55AM William Blair Downgrades Apellis Pharmaceuticals (APLS) to Market Perform

Mar 31, 2026 11:51AM Baird Downgrades Apellis Pharmaceuticals (APLS) to Neutral

Mar 31, 2026 11:45AM Needham Downgrades Apellis Pharmaceuticals (APLS) to Hold

Mar 31, 2026 10:17AM Apellis Pharmaceuticals (APLS) call put ratio 1.2 calls to 1 put after Biogen (BIIB) acquires

Mar 31, 2026 10:11AM Wolfe Research on Apellis Pharmaceuticals (APLS): Biogen deal 'makes sense' at 'good time to sell'

Mar 31, 2026 06:50AM Biogen to acquire Apellis Pharmaceuticals for $5.6 billion or $41/sh plus CVR

Mar 18, 2026 06:56AM Apellis Pharmaceuticals (APLS) PT Lowered to $31 at Cantor Fitzgerald

Mar 13, 2026 03:27AM Roth/MKM Starts Apellis Pharmaceuticals (APLS) at Buy

Mar 13, 2026 03:27AM Roth/MKM Starts Apellis Pharmaceuticals (APLS) at Buy

Mar 13, 2026 03:27AM Roth/MKM Starts Apellis Pharmaceuticals (APLS) at Buy

Feb 25, 2026 06:40AM Apellis Pharmaceuticals (APLS) PT Raised to $48 at H.C. Wainwright

Feb 24, 2026 05:15PM Apellis Pharmaceuticals, Inc. (APLS) Tops Q4 EPS by 85c

Jan 27, 2026 05:18PM TTM Technologies, Dutch Bros among companies joining S&P MidCap 400; Others join S&P SmallCap 600

Jan 21, 2026 05:18AM BofA Securities Upgrades Apellis Pharmaceuticals (APLS) to Buy

Jan 16, 2026 07:02AM Apellis Pharmaceuticals (APLS) Reiterated at Overweight by Cantor Fitzgerald

Jan 13, 2026 07:11AM Apellis Pharmaceuticals (APLS) PT Lowered to $28 at Needham

Jan 13, 2026 07:11AM Apellis Pharmaceuticals (APLS) Reiterated at Overweight by Cantor Fitzgerald

Jan 12, 2026 01:45PM Goldman Sachs on Apellis Pharmaceuticals (APLS): 'we see limited near-term growth levers'

Jan 2, 2026 10:00PM Here are Mizuho's top Biotech pick for 2026

Dec 21, 2025 08:00PM Here's the list of top biotech stocks to own for 2026

Dec 19, 2025 07:31AM Apellis Pharmaceuticals (APLS) PT Lowered to $48 at Stifel - Aims to Grow in 2026

Dec 15, 2025 04:30AM William Blair Reiterates Outperform Rating on Apellis Pharmaceuticals (APLS)

Nov 12, 2025 07:02AM Apellis reports SYFOVRE delayed geographic atrophy progression by 1.5 years

Nov 3, 2025 06:41AM Apellis Pharmaceuticals (APLS) PT Lowered to $19 at Mizuho

Oct 30, 2025 08:17AM Apellis Pharmaceuticals, Inc. (APLS) Tops Q3 EPS by 12c

Oct 21, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Apellis Pharmaceuticals (APLS)

Oct 20, 2025 05:12AM Apellis Pharmaceuticals (APLS) PT Raised to $29 at BofA Securities

Oct 20, 2025 05:08AM Apellis Pharmaceuticals (APLS) PT Raised to $22 at RBC Capital

Oct 15, 2025 05:11AM Wells Fargo Upgrades Apellis Pharmaceuticals (APLS) to Overweight

Sep 29, 2025 06:58AM H.C. Wainwright Reiterates Buy Rating on Apellis Pharmaceuticals (APLS)

Sep 26, 2025 05:08AM Goldman Sachs Downgrades Apellis Pharmaceuticals (APLS) to Sell

Aug 1, 2025 08:40AM Apellis Pharmaceuticals (APLS) PT Raised to $40 at Cantor Fitzgerald

Jul 31, 2025 07:09AM Apellis Pharmaceuticals, Inc. (APLS) Tops Q2 EPS by 15c

Jul 30, 2025 08:34AM Apellis Pharmaceuticals (APLS) PT Raised to $22 at Scotiabank

Jul 29, 2025 12:12PM Apellis Pharmaceuticals (APLS) PT Raised to $21 at Mizuho

Jul 29, 2025 08:36AM Cantor Fitzgerald Reiterates Overweight Rating on Apellis Pharmaceuticals (APLS)

Jul 29, 2025 07:07AM FDA approves Apellis' EMPAVELI as first C3G and primary IC-MPGN treatment

Jul 14, 2025 06:56AM H.C. Wainwright Reiterates Buy Rating on Apellis Pharmaceuticals (APLS)

Jul 10, 2025 07:28AM William Blair Reiterates Outperform Rating on Apellis Pharmaceuticals (APLS)

Jul 10, 2025 06:40AM Cantor Fitzgerald Reiterates Overweight Rating on Apellis Pharmaceuticals (APLS)

Jul 2, 2025 06:36AM Mizuho Reiterates Neutral Rating on Apellis Pharmaceuticals (APLS)

View More Recent Stories View Older Stories